1 Erratum to: Clin Pharmacokinet (2014) 53:837–847 DOI 10.1007/s40262-014-0161-2

Page 837; column 2, para 4: The first key point, which previously read:

Vandetanib may lead to greater exposure to octamer transcription factor-2 substrates or P-glycoprotein substrates when co-administered.

Should read:

Vandetanib may lead to greater exposure to organic cation transporter 2 substrates or P-glycoprotein substrates when co-administered.